Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (94) clinical trials

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

This is a Phase 1b, open-label, dose-escalation cohort study. The study will consist of a dose escalation assessment of the safety and tolerability of ACY-241 administered concurrently in combination with ipilimumab and nivolumab to patients with advanced melanoma. Treatment will be divided into induction and maintenance phases. Determine the safety, ...

Phase

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.

Phase

A Study of rSIFN-co in Subjects With Advanced Solid Tumors

The Dose-Escalation Cohort will consist of the Pretreatment Phase, the Treatment Phase, the Extension Phase, Discontinuation and Follow-up. The Pretreatment Phase will include a Consent and Screening Period. The Treatment Phase will consist of the Lead in Period and first 21-day cycle of treatment during which subjects will be monitored ...

Phase

Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors

OBJECTIVES: Primary - To determine the tolerance and toxicity profile of ipilimumab at a range of doses up to, but not exceeding, the highest dose tolerated in patients 21 years of age or younger with advanced or refractory solid tumors. - To assess the pharmacokinetics of ipilimumab in patients with ...

Phase

Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

OBJECTIVES: Primary - To describe the safety and toxicity of the combination of dasatinib and bevacizumab in patients with advanced solid tumors that have progressed on standard therapy. - To find the maximum tolerated dose or recommended phase II dose of this combination. - To describe the biochemical changes in ...

Phase

Interferon Alfa-2b in Treating Patients Who Have Undergone Surgery for High-Risk or Metastatic Melanoma

OBJECTIVES: Primary - To determine whether selection of the optimal dose of interferon alfa-2b can be made using signal transduction data in patients who have undergone surgical resection for high-risk or metastatic melanoma. Secondary - To determine the tolerability of this drug when administered at an optimized dose, in terms ...

Phase

Safety Tolerability and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and ...

Phase

Clinical Usefulness of Optical Skin Biopsy

Traditional biopsy requires the removal, fixation, and staining of tissues from the human body. Its procedure is invasive and painful. Non-invasive in vivo optical biopsy is thus required, which should provide non-invasive, highly penetrative, three-dimensional (3D) imaging with sub-micron spatial resolution. Optical biopsy based on scanning two-photon fluorescence microscopy (TPFM) ...

Phase

Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab, vemurafenib and cobimetinib will ...

Phase

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

PRIMARY OBJECTIVE: I. To determine the safety of three different stereotactic radiosurgery (SRS) radiation arms in combination with pembrolizumab for melanoma and non-small cell lung cancer (NSCLC) brain metastasis (BM) patients. SECONDARY OBJECTIVES: I. To evaluate intracranial outcomes - control of the treated lesion in the brain with SRS+ pembrolizumab ...

Phase